US FDA approves Gilead's drug for deadly liver infection

Food and Drug Administration ‌said on Friday it ‌approved Gilead Sciences' drug for a ​rare and deadly liver infection that ...

Gilead Sciences Gets FDA Green Light for Chronic HDV Drug

Gilead Sciences received accelerated approval for a chronic hepatitis delta virus treatment from the Food and Drug Administration. The FDA said the Hepcludex treatment, known also as bulevirtide-gmod, ...

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the ...